Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years
about
Bone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women's health practiceInfluence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension studyVitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis.The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension studyHigh bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients.Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder.Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis.Trends in hip fracture rates in Taiwan: a nationwide study from 1996 to 2010.Osteoporosis: Treat or Let Die Twice More Likely.Spanish consensus on treat to target for osteoporosis.Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.Trochanteric fragility fractures : Treatment using the cement-augmented proximal femoral nail antirotation.Effects of Long-term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis.Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment.
P2860
Q28066185-3D26A818-0417-46C5-B4C6-C3BA3CD6ACF2Q33612987-A577F584-BFDB-47A7-9879-1316345C870FQ33749157-EE44762A-6D34-48CF-873C-B9D691E3FA59Q36309353-4A0735FC-AA55-486F-9104-58447A1EA6D7Q37488814-53C38E24-D672-4689-A533-34E735DDE02AQ37609131-A0F21866-CFFE-4B7E-A9D2-8865D6027FFDQ38758007-0843D329-A461-4624-87A3-88122F0FB3F9Q38793382-031E607A-9213-43D7-B70D-09AFB335E612Q39178635-5F5119A2-6137-4E5C-947B-ED0E7A086CC8Q41546766-D2CBE416-785A-45BD-9DAE-8A2428205816Q47596255-EC6D4F5B-C814-479E-8EBE-09B91BDE96FCQ50142958-C401525F-7727-4436-A794-94F7B46188EAQ51310137-8BAE3176-BFC6-4CA8-BAE0-39A31BC375ABQ52577840-6E1D2A89-4ABF-4EBB-8B44-505DCEFAE637Q55269687-20400F19-00D4-422D-A19E-21A4ED3C79E0
P2860
Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Further reductions in nonverte ...... mineral density after 3 years
@ast
Further reductions in nonverte ...... mineral density after 3 years
@en
type
label
Further reductions in nonverte ...... mineral density after 3 years
@ast
Further reductions in nonverte ...... mineral density after 3 years
@en
prefLabel
Further reductions in nonverte ...... mineral density after 3 years
@ast
Further reductions in nonverte ...... mineral density after 3 years
@en
P2093
P2860
P1476
Further reductions in nonverte ...... mineral density after 3 years
@en
P2093
C D O'Malley
C Libanati
C Zapalowski
D L Kendler
E M Lewiecki
J D Adachi
J-Y Reginster
N S Daizadeh
P2860
P2888
P304
P356
10.1007/S00198-015-3179-X
P407
P577
2015-06-12T00:00:00Z